Anti-IL-13 monoclonal antibody Pregnancy: US labelling (section 8.1): available data in pregnant women are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage or other adverse outcomes. Monoclonal antibodies are actively transported across the placenta, so the drug may be present in infants exposed in utero (greatest transfer in the third trimester). No effects on embryo-foetal development in cynomolgus monkeys at doses up to 18 times the human exposure at the maximum recommended human dose.

Lebrikizumab

Brand names: Ebglyss

Lebrikizumab is a subcutaneous monoclonal antibody used for moderate-to-severe atopic dermatitis (eczema) in adults and adolescents who are candidates for systemic therapy.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: 500 mg (two 250 mg injections) at Week 0 and at Week 2, followed by 250 mg (one injection) every 2 weeks until Week 16 or later, when adequate clinical response is achieved; maintenance 250 mg every 4 weeks or 250 mg every 8 weeks

Route: Subcutaneous injection

Frequency: 500 mg at Weeks 0 and 2, then 250 mg every 2 weeks to Week 16 or later; then 250 mg every 4 weeks or every 8 weeks as maintenance

Taken from the US prescribing information (EBGLYSS, moderate-to-severe atopic dermatitis) — no UK SPC posology was present in the fetched bundle, so verify against the UK SPC before use. Complete all age-appropriate vaccinations according to current immunisation guidelines prior to starting treatment. May be used with or without topical corticosteroids; topical calcineurin inhibitors may be used but reserved for sensitive areas only (face, neck, intertriginous and genital areas). Missed dose: administer as soon as possible, then resume dosing at the regular scheduled time. Paediatric: safety and effectiveness are established in patients 12 years and older weighing at least 40 kg (US label states no separate per-kg or reduced dose for this group); not established below 12 years or in patients 12 years and older weighing less than 40 kg. Intended for use under the guidance of a healthcare professional; adults may self-inject and caregivers may inject after training. Injection sites: abdomen, thigh and back of upper arm (upper arm by caregiver or healthcare provider); alternate sites, do not inject within 5 cm (2 inches) of the navel or into skin that is tender, bruised, red, hard, or affected by atopic dermatitis or skin lesions. Available as 250 mg/2 mL single-dose prefilled pen and 250 mg/2 mL (125 mg/mL) single-dose prefilled syringe.

Dose auto-extracted from US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

Prior serious hypersensitivity to lebrikizumab-lbkz or any of the excipients

Side effects

Conjunctivitis (most frequently reported eye disorder; more frequent than placebo)
Injection site reactions
Herpes zoster
Keratitis
Hypersensitivity reactions including angioedema and urticaria

Interactions

Live vaccines — avoid use during treatment; complete all age-appropriate vaccinations before initiating (US label section 5.4). No dedicated drug interaction section was present in the fetched source.

Clinical monograph

How it works

It is a humanised monoclonal antibody that binds interleukin-13 with high affinity, blocking IL-13 signalling, a key driver of type 2 inflammation in atopic dermatitis.

Prescribing in practice

Conjunctivitis is a recognised class-related adverse effect; advise patients to report new or worsening eye symptoms and assess if persistent.
Live vaccines should be avoided during treatment, and patients should be screened and treated for active helminth or other relevant infections before starting.
Given by subcutaneous injection with an initial loading phase followed by maintenance dosing; it may be used with or without topical corticosteroids.

Monitoring

Monitor clinical response and for ocular adverse effects such as conjunctivitis and hypersensitivity reactions.

Counselling the patient

Report red, sore or itchy eyes, as conjunctivitis can occur with this treatment.
Tell your healthcare team before having any vaccinations, particularly live vaccines.
Continue using your emollients and any topical treatments as advised.

Evidence & guidelines

Lebrikizumab's efficacy in moderate-to-severe atopic dermatitis was demonstrated in the ADvocate and ADhere phase 3 trials, and it is appraised by NICE for this indication.

Reference: NICE TA970; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways